Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fed Conditions
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to compare the rate of absorption and the oral
bioavailability of a test formulation of doxycycline monohydrate 1 x 25 mg (5mL) oral
suspension manufactured by IVAX Pharmaceuticals, Inc. and distributed by TEVA Pharmaceuticals
USA to an equivalent oral dose of the commercially available reference product, Vibramycin
Monohydrate® manufactured by Pfizer, Inc. Following an overnight fast of at least 10 hours,
subjects consumed a standard high-calorie. high-fat breakfast meal. This standard breakfast
meal began 30 minutes prior to each dose.